Launch of new GeneGnome XRQ chemiluminescence imaging system
Cambridge, UK: Syngene, a world-leading manufacturer of image analysis solutions, is delighted to introduce its new GeneGnome XRQ, a dedicated chemiluminescence imaging system designed to rapidly and accurately image chemiluminescent Western blots.
The new, blue GeneGnome XRQ houses a high-quality F/0.95 fixed focus, cooled camera with on chip integration and GeneSys software, all packed into a light-tight darkroom. Based on the optimised short camera to sample distance technology of the award winning GeneGnome, the GeneGnome XRQ saves scientists time because they simply load a blot into the systems slide-out drawer and capture perfect chemiluminescent images without using expensive X-ray film.
GeneSys software can be set up for single or multi-image capture with different exposure times simultaneously, ensuring scientists always generate images which have increased dynamic range compared to film, to accurately detect and quantify proteins, even when bands are faint. The software also makes it easy to add visible markers by automatically overlaying the chemiluminescent image with the white light marker image. These features make imaging chemiluminescent Westerns a simple task and significantly accelerate the imaging workflow.
The GeneGnome XRQ includes long-life white LED EPI lighting for viewing visible markers on the blot and requires little bench space. The system is also easily connected to a PC and printer (if required), for researchers to automatically calculate molecular weight and protein quantity using GeneTools, Syngenes image analysis software, as well as allowing storage or printing of high resolution and publication quality images.
Researchers find achieving the right conditions for generating perfectly exposed chemi blots time-consuming and expensive, especially if they are using X-ray film, states Dr Martin Biggs, Divisional Manager at Syngene. Our GeneGnome XRQ system combines ease of use with unrivalled sensitivity offering the perfect solution to these issues. Using this great technology even scientists new to analysing chemiluminescent Westerns, can look forward to effortlessly producing true to life imaging results every time.
Hi Claude - the price has bounced nicely this week!
SDI are very illiquid, and it only takes a few buys or sells to move the price up or down a few pence.
For a small-cap company the shareholder list is incredible - a series of prime, blue-chip institutions and big names. But I'm sure some of the places from prior fundraising have also taken a bit of profit off the table, which is fair enough.
I noticed that Vitec (VTC) issued a very good trading statement yesterday. They produce high-end camera accessories, supports etc, and in particular they stated:
"The Photographic Division performed well and the market continues to show signs of recovery."
Hopefully this has some positive ramifications for SDI's Opus and Atik businesses.
Cambridge, UK: Syngene, a world-leading manufacturer of image analysis solutions, today announced its G:BOX Chemi XRQ multi-application imager is being used in the School of Biochemistry at the University of Bristol, one of UKâs best biochemistry departments, in the laboratory of Prof. Jo Adams, to rapidly generate more accurate images of extracellular matrix (ECM) proteins associated with fibrosis, angiogenesis and wound healing.
Researchers in the School of Biochemistry are using a G:BOX Chemi XRQ multi-application system for imaging ECL-based chemiluminescent Western blots to accurately detect changes in thrombospondins, secreted glycoproteins of the extracellular matrix. The data produced are providing information which the scientists at the University of Bristol are using to understand how these proteins regulate the interaction between cells and the ECM.
Excellent report of SDI's AGM posted by "hastings" which I hope he won't mind me copying here:
"There was only one other private shareholder present and he had travelled considerably further than me, coming all the way down from Scotland.
As far as the board went, all Directors were present with the addition of representatives from each division of the group, so it was nice to be able to ask a few questions to new faces.
Although the meeting was reasonably short Ken Ford (Chairman) reiterated the message as in the release that morning regarding trading being in line with expectations and that they view the current financial year very positively.
Some points of interest, the other shareholder present asked as to how they identify the acquisition targets.
Ford introduced us to a seemingly very knowledgeable chap (name escapes me) who for a number of years was employed by Judges Scientific but who has more recently been assisting SDI in this field.
The man in question pointed out that there are numerous company's out there for SDI to acquire as the space is very fragmented. However, it takes time and a lot of groundwork to secure the right fit.
Ford and Creedon are of course deeply involved in the process and work with him in this area.
It was also added, that when you have made a few of these buys, subjects begin to seek you out as opposed to the other way round, which can make the process somewhat easier.
Suffice to say though that they are not at present ready for another buy, but continue to look pointing out it is very much key to their progression.
My conclusion is that I think we can assume that there will be another one in the not so distant future.
All current arms are profitable and going well, even the Synoptics business, which although enjoying a chunk of sizeable revenue has struggled over the years.
Creedon said cost savings, reorganisation and new products have turned this around.
Pro-Reveal continues to make progress albeit slowly and they are currently (still) waiting to hear back on the potential for a procurement programme from the DOH/NHS.
That would be very welcome and provide for a really good boost.
They aren't however surprised by the timing or for that matter seemingly concerned, as they view the product as a potentially nice edition to the rest and it is certainly in the right place given the guidance etc, so it remains a case of waiting and watching with that.
In terms of a future placing (not on the cards at present) they are aware of retail investor interest and would now certainly consider making some kind of provision alongside an institutional placing, the latter of which they say would see plenty of support.
I asked the question if Brexit presented any worries for any arms of the business, but each head said that was not of concern to them and they couldn't envisage any problems.
Ford also asked the two of us present our views on commencing dividend payments, which he said when/if implemented would be very well covered.
For my part, I said that I would rather see the money ploughed back into the business until a scaling up had been reached that would ensure a sustainable progressive dividend for the medium to long term as opposed to a sort of token dividend that some companies often opt for.
All in all, there seems to be a really positive mood prevailing, although they clearly do not want to overplay anything and Creedon just tells it as it is.
That said I can envisage at some point an upgrade coming through as they certainly have some decent businesses going well with prospects for organic growth that can be enhanced by further bolt-on buys.
For now at the current price of 23.5p the shares do not look expensive to me trading on a PER of 11 falling to 10 (sector average is 19) with a PEG of 0.7 which looks well worth holding on to in the near term, with scope for further upside in the future."
Launch of NEW Chromogenic ID Media Software Module for ISO® 9308-1 Compliant Plates
Cambridge, UK: Synbiosis, a long-established, expert manufacturer of automated microbiological systems, today announced its Chromogenic ID software for use with Synbiosis colony counters has a new validated module for automatic identification of bacteria cultured on Liofilchem and Merck ISO 9308-1 compliant chromogenic media. Using this upgraded software allows microbiologists to precisely identify a range of coliforms in drinking water and disinfected pool water.
The new Chromogenic ID software module for use with Synbiosis ChromoZona, ProtoCOL 3, and Protos 3 automated colony identification systems, guarantees that using these systems patent digital colour imaging technology microbiologists can generate true to life colour plate images of E.coli and coliforms cultured on Liofilchem Chromatic Coliform Agar ISO and Mercks Chromocult® Coliform Agar.
By analysing the plate images, the Chromogenic ID software can easily distinguish between purple/violet and salmon pink/red colonies, providing quick identification of E. coli, Klebsiella spp., Enterobacter spp. and Citrobacter spp.on these ISO® 9308-1 compliant chromogenic plates. This reduces misidentification, providing consistent data no matter when or which microbiologist is reading the plate. The plate images can then be stored in a secure SQL database for cross checking if necessary, and means the software is ideally suited for use in quality accredited testing laboratories.
To find out more about this exciting new Chromogenic ID Media Software Module scientists can click the link: hxxp://www.synbiosis.com/chromogenic-id/
Eye identification of bacteria using chromogenic media depends on the lighting above and below the plate, as well as the colour vision and experience of the microbiologist comments Kate George, Sales & Technical Director at Synbiosis. Our new software module for Liofilchem and Mercks ISO 9308-1 compliant plates is a great solution to the problems associated with this error prone manual method creating a standardised, consistent and objective test. This means scientists using ChromoZona, ProtoCOL 3 and Protos 3 systems can be confident of correctly identifying water borne pathogens every time.
Nicely in line to date, and to say at this stage that the rest of the year is viewed "very positively" is rather bullish:
"The Group is trading in line with our expectations and the outlook for the year is unchanged. We are encouraged by the pace of the integration of Applied Thermal Control and the Board views the current financial year very positively."
Syngene introduces G:BOX mini multi-application imaging system - fast, high performance gel and blot imaging in one compact system.
Cambridge, UK: Syngene, a world-leading manufacturer of image analysis solutions, today introduced the G:BOX mini, a compact, upgradable, multi-application system for all types of gel and Western blot imaging. Featuring a motorized stage, high performance camera and the option to add HI-LED lighting, this system is an ideal solution for laboratories that need application flexibility without compromising on the accuracy of results.
Building on the technology of the popular G:BOX range, the G:BOX mini with its high performance 0.95 lens, 6 or 9-megapixel camera, can image and resolve close bands or spots even on complex 2D gels. Combining a unique motorized stage and super-cooled camera, the G:BOX mini, unlike many other imaging systems, generates true-to-life, low-noise optical images not just digitally enhanced ones. These features make the G:BOX mini a compact powerhouse and means scientists will not require separate systems for accurately imaging chemiluminescent Westerns, fluorescent and stain-free gels, visible fluorescent or IR Western blots.
With the option to add high intensity blue, green, red and infra-red HI-LEDS that are up to 200 times brighter than standard LEDs, the new G:BOX mini guarantees faster exposure times than most compact CCD-based systems. The application-driven GeneSys software which controls the G:BOX mini makes it quick and simple for researchers to set-up their optimum filter and lighting combinations to image multiplexed fluorescent and IR dyes, DNA and stain-free protein gels. The software also auto-calibrates to each gel or blots size, ensuring great images every time.
The compact G:BOX mini is connected to an external PC and printer offering superior performance and flexibility compared to tablet based imagers, allowing scientists to run the GeneSys touch screen controls on a large screen, store a huge number of images and rapidly print publication quality pictures.
The trend in image analysis is for small footprint equipment that can rapidly generate high quality, chemi, fluorescence, colorimetric and now stain-free gel images, explains Dr Martin Biggs, Sales Manager at Syngene, Were excited to introduce our G:BOX mini because this system perfectly fits that need. Weve combined so much cutting-edge, easily upgradable technology into this compact imager that scientists can accurately analyse simple gel docs right through to multiplexed fluorescence applications, now and in the future, using just one clever system.
SDI was again tipped as a Buy in Saturday's edition of SCSW, with quite a lengthy summary of the results, prospects and the Finncap EPS upgrade. It concluded "I remain a buyer with more deals in the wings".
I'm surprised it didn't attract more buying - SDI is one of only a very few companies covered in SCSW which is on a P/E of less than 20-25!
SDI are on a forward P/E of 11.6 based on 2.2p EPS (1.9p EPS this year) - and that's without any further earnings-enhancing acquisitions.
"Scientific Digital Imaging (AIM: SDI, "SDI" or the "Company") was notified on 24 August 2017 that, on the same day, Ken Ford, Chairman of the Company, purchased 100,000 ordinary shares of 1p each in the Company at 26.45p per share. The Company was also notified that, on the same day, David Tilston, Non-Executive Director of the Company, purchased 25,000 ordinary shares of 1p each in the Company at 26.45p per share."
Another excellent and nicely earnings-enhancing acquisition. Looks like a cheap price too given £1.2m maximum consideration for a likely £200,000 PBT given lower sales and marketing investment costs after 2016:
The recurring income and overseas sales are also encouraging, and I'm assuming there's potential for integration/sales synergies with SDI's existing product portfolio as a "complementary businesses" with "areas within ATC with potential for growth".
"The New Atik Horizon CMOS Camera
By Jo on July 27th, 2017
Since announcing development of our first CMOS camera in May, weve been busy getting things ready for release. Weve locked down our case design, boosted our cooling and now have our full set of provisional specifications. So, without further ado, let us introduce you to the Atik Horizon....
....Last week we put out a call for BETA testers for the new Atik Horizon. With such an overwhelming response, we are currently not accepting any new applications for BETA Testers. The initial production run is extremely limited, and weve had a huge number of applicants already. If youve applied, we like to say a huge thank you for your interest and will get back to you about next steps in due course.
We anticipate the full release to follow in early October....."
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.